Particle-mediated DNA vaccines employ a physical, intracellular delivery device to achieve the deposition of plasmid DNA-based expression vectors directly into the interior of cells of the skin. The resultant bolus of transient antigen expression in keratinocytes and trafficking dendritic cells results in the induction of humoral and cellular immune responses in various animal models and humans, mimicking characteristics of live or live-vectored vaccines. Ultimately, DNA vaccine success in the clinic will depend on both the successful intracellular delivery of a plasmid vector and an immunostimulator or adjuvant to maximise humoral and cellular immune responses to the encoded antigen(s). To this end, recent DNA vaccine clinical trials are confirming the importance of an intracellular delivery system, while preclinical studies in animal models are demonstrating the feasibility of augmenting responses through the use of DNA-encoded immunostimulators. Particle-mediated DNA vaccines represent a promising tool for developing candidate vaccines against some of the more difficult infectious, parasitic and oncologic disease targets.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14712598.4.6.889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improved DNA Vaccine Delivery with Needle-Free Injection Systems.
Vaccines (Basel)
January 2023
PharmaJet, 400 Corporate Circle, Unit N, Golden, CO 80401, USA.
DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability. However, a major drawback of candidate DNA vaccines delivered by needle and syringe is the poor immunogenicity associated with inefficient cellular uptake of the DNA. This uptake is essential because the target vaccine antigen is produced within cells and then presented to the immune system.
View Article and Find Full Text PDFViral Particle-Mediated SAMHD1 Depletion Sensitizes Refractory Glioblastoma to DNA-Damaging Therapeutics by Impairing Homologous Recombination.
Cancers (Basel)
September 2022
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
The current standard-of-care treatment for glioblastoma includes DNA damaging agents, γ-irradiation (IR) and temozolomide (TMZ). These treatments fail frequently and there is limited alternative strategy. Therefore, identifying a new therapeutic target is urgently needed to develop a strategy that improves the efficacy of the existing treatments.
View Article and Find Full Text PDFA DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.
NPJ Vaccines
April 2022
U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, MD, 21702, USA.
We have previously shown that DNA vaccines expressing codon optimized alphavirus envelope glycoprotein genes protect both mice and nonhuman primates from viral challenge when delivered by particle-mediated epidermal delivery (PMED) or intramuscular (IM) electroporation (EP). Another technology with fewer logistical drawbacks is disposable syringe jet injection (DSJI) devices developed by PharmaJet, Inc. These needle-free jet injection systems are spring-powered and capable of delivering vaccines either IM or into the dermis (ID).
View Article and Find Full Text PDFAlphaherpesvirus-induced activation of plasmacytoid dendritic cells depends on the viral glycoprotein gD and is inhibited by non-infectious light particles.
PLoS Pathog
November 2021
Department of Virology, Parasitology, Immunology-Faculty of Veterinary Medicine-Ghent University, Merelbeke, Belgium.
Plasmacytoid dendritic cells (pDC) are important innate immune cells during the onset of viral infections as they are specialized in the production of massive amounts of antiviral type I interferon (IFN). Alphaherpesviruses such as herpes simplex virus (HSV) or pseudorabies virus (PRV) are double stranded DNA viruses and potent stimulators of pDC. Detailed information on how PRV activates porcine pDC is lacking.
View Article and Find Full Text PDFEffects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques.
NPJ Vaccines
March 2021
Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
Article Synopsis
- An effective vaccine to prevent HIV transmission is still under development, and probiotic therapy has been proposed as a way to potentially boost immune responses during vaccination.
- In a study with rhesus macaques, researchers tested whether daily oral probiotics could enhance the effectiveness of SIV/HIV vaccines, but found no significant improvements in immune responses or protection against infection.
- The findings suggest that while probiotics are safe to use with SIV/HIV vaccinations, they did not enhance the vaccine’s effectiveness, indicating more research is needed to find better ways to leverage the microbiome for improving vaccine responses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!